Mammary Cell News Volume 6.27 | Jul 17 2014

Triple Negative Breast Cancer Therapy with CDK1 siRNA Delivered by Cationic Lipid Assisted PEG-PLA Nanoparticles
The authors report a molecularly targeted and synthetic lethality-based siRNA therapy for triple-negative breast cancer treatment, using cationic lipid assisted poly(ethylene glycol)-b-poly(d,l-lactide) (PEG-PLA) nanoparticles as the siRNA carrier. [J Control Release] Abstract

Surgery-Induced Wound Response Promotes Stem-Like and Tumor-Initiating Features of Breast Cancer Cells, via STAT3 Signaling
Researchers discovered that post-surgery wound fluids induced the enrichment of breast cancer cells with stem-like phenotypes, via activation of Signal Transducer and Activator of Transcription 3 (STAT3). [Oncotarget]
Full Article

Metabolic Differences in Breast Cancer Stem Cells and Differentiated Progeny
Researchers investigated the metabolic phenotype of breast cancer stem cells (BCSCs) and their differentiated progeny. Luminal, basal, and claudin-low breast cancer cell lines were propagated as mammospheres enriched in BCSCs. [Breast Cancer Res Treat] Abstract

Both Canonical and Non-Canonical Wnt Signaling Independently Promote Stem Cell Growth in Mammospheres
Ex vivo mammosphere cultures were established from both wild-type and Wnt1 transgenic mice and were analyzed in response to manipulation of both canonical and non-canonical Wnt signaling. [PLoS One] Full Article

The Aryl Hydrocarbon Receptor Ligand Omeprazole Inhibits Breast Cancer Cell Invasion and Metastasis
Triple negative MDA-MB-231 breast cancer cells were treated with eight aryl hydrocarbon receptor-active pharmaceuticals including 4-hydroxtamoxifen, flutamide leflunomide, mexiletine, nimodipine, omeprazole, sulindac and tranilast, and the effects of these compounds on cell proliferation and cell migration were examined. [BMC Cancer] Abstract | Full Article

Neuregulin-1 Induces Cancer Stem Cell Characteristics in Breast Cancer Cell Lines
Researchers show that neuregulin-1 treatment induced cancer stem cell (CSC) characteristics in breast cancer cell lines. Using breast cancer cell lines, MCF-7, SKBr-3 and MDA-MB 468, changes related to CSC characteristics were analyzed. [Oncol Rep] Abstract

CLINICAL RESEARCH

A Randomized Phase II Presurgical Trial of Transdermal 4-Hydroxytamoxifen Gel versus Oral Tamoxifen in Women with Ductal Carcinoma In Situ of the Breast
Local transdermal therapy to the breast may achieve effective target-organ drug delivery, while diminishing systemic effects. Investigators conducted a randomized, double-blind, placebo-controlled Phase II trial comparing transdermal 4-hydroxytamoxifen gel to oral tamoxifen in women with ductal carcinoma in situ. [Clin Cancer Res] Abstract | Press Release

Phase I Study of Olaparib in Combination with Liposomal Doxorubicin in Patients with Advanced Solid Tumors
Olaparib, an oral PARP inhibitor, has shown antitumor activity as monotherapy in patients with germline BRCA1/2-mutated breast and ovarian cancer. Investigators evaluated olaparib capsules in combination with liposomal doxorubicin in patients with advanced solid tumors. [Br J Cancer] Full Article

Differential Effects of Serum from Patients Administered Distinct Anesthetic Techniques on Apoptosis in Breast Cancer Cells In Vitro: A Pilot Study
Using serum from breast cancer surgery patients randomized to receive distinct anesthetic techniques, scientists investigated its effect on apoptosis in estrogen receptor-negative breast cancer cells in vitro. [Br J Anaesth] Abstract | Press Release

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Imugene Engages Mymetics to Manufacture HER-Vaxx Cancer Immunotherapy
Imugene Limited has engaged Mymetics SA to exclusively manufacture and develop its cancer immunotherapy HER-Vaxx. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. [Imugene Limited] Press Release

Lilly and Immunocore Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies
Eli Lilly and Company and Immunocore Limited announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Using Immunocore’s Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body’s own immune system to attack cancer cells. [Eli Lilly and Company] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

NEW Postdoctoral Fellow – Mammary Stem Cell Biology (University of Amsterdam)

NEW Postdoctoral Fellow – Mammary Differentiation (University of British Columbia)

Postdoctoral Fellow – Molecular Cancer Biology (University of Texas Health Science Center at San Antonio)

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

PhD Candidate – Mammary Stem Cell Biology (University of Amsterdam)

Postdoctoral Fellow – Breast Cancer Biology (University of Tennessee Health Science Center)

Postdoctoral Scholar – Cancer and RNA Research (Northwestern University)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.